Page 18 - Michael Erman News Today

The U.S. Food and Drug Administration said on Tuesday it was investigating cancer therapies made by Gilead Sciences, Johnson & Johnson, Novartis and others over the risk of hospitalizations and...

Pfizer Inc is disappointed in its performance versus rival GSK in the RSV vaccine market and is working to pick up market share in 2024, Chief Financial Officer David Denton said on Tuesday. ...

(Reuters) -The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies made by companies such as Gilead Sciences, Johnson & Johnson and Novartis over the risk of hospitalizations and death due to a serious safety issue. The FDA said it had received reports of T-cell malignancies, which refer to a group of blood disorders including lymphomas and leukemias, after treatment with CAR-T therapies or chimeric antigen receptor T-cell therapies. Since 2017, s...

Over 15 million people in the United States, around 4.5% of the population, had received the updated COVID-19 shots by October 27, lagging behind last years vaccinations.

WASHINGTON (Reuters) -Over 15 million people in the United States, around 4.5% of the population, had received the updated COVID-19 shots by Oct. 27, a Department of Health and Human Services (HHS) spokesperson said on Wednesday, lagging behind last year's vaccinations. Close to 23 million people had received updated boosters as of Oct. 26 last year, U.S. Centers for Disease Control and Prevention (CDC) data shows. "As of Oct. 27, more than 15 million Americans have received the update...

Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. The British drugmaker's early advantage may be tied to its positioning as the lone RSV shot offered by CVS Health, the biggest pharmacy chain in the U.S. and a dominant player in the retail vaccine market, analysts and industry experts say. Price may also be playing a role, according to...

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs wont shrink their businesses.

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs wont shrink their businesses....

Bristol Myers Squibb on Thursday pushed back by a year the time frame for its new-product portfolio to hit $10 billion in revenue as the sales ramp-up of medicines such as psoriasis treatment Sotyktu and multiple sclerosis drug Zeposia takes longer than initially projected.

(Reuters) -Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy. Sales of molnupiravir, the COVID-19 antiviral pill sold under brand name Lagevrio, jumped 47% to $640 million in the quarter, crushing Wall Street estimates of $120 million, according to LSEG data. Molnupiravir was initially hailed as a potential breakthrough when few...